Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- DBV.PA
- Price
- 1.31
- Stock movement down
- -0.01 (-0.45%)
- Company name
- DBV Technologies S.A.
- Exchange
- (PA ,
- Currency
- EUR )
- Sector
- Healthcare >Biotechnology
- Market cap
- 134.79M
- Ent value
- 127.37M
- Price/Sales
- 11.78
- Price/Book
- 2.49
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -35.96%
- 1 year return
- 8.60%
- 3 year return
- -19.74%
- 5 year return
- -31.15%
- 10 year return
- -30.20%
Last updated: 2025-04-16
DIVIDENDS
DBV.PA does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 11.78 |
| Price to Book | 2.49 |
| EV to Sales | 11.13 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 102.58M |
| EPS (TTM) | -1.06 |
| FCF per share (TTM) | -1.13 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 11.44M |
| Gross profit (TTM) | 11.44M |
| Operating income (TTM) | -104.65M |
| Net income (TTM) | -102.09M |
| EPS (TTM) | -1.06 |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | 100.00% |
| Operating margin (TTM) | -914.52% |
| Profit margin (TTM) | -892.15% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 46.44M |
| Net receivables | 20.10M |
| Total current assets | 68.76M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 18.97M |
| Total assets | 93.06M |
| Accounts payable | 22.50M |
| Short/Current long term debt | 8.12M |
| Total current liabilities | 30.91M |
| Total liabilities | 39.02M |
| Shareholder's equity | 54.03M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -105.91M |
| Capital expenditures (TTM) | 2.81M |
| Free cash flow (TTM) | -108.72M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -188.93% |
| Return on Assets | -109.71% |
| Return on Invested Capital | -185.24% |
| Cash Return on Invested Capital | -197.27% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 1.32 |
| Daily high | 1.35 |
| Daily low | 1.28 |
| Daily Volume | 521K |
| All-time high | 83.51 |
| 1y analyst estimate | 2.46 |
| Beta | 0.86 |
| EPS (TTM) | -1.06 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| DBV.PA | S&P500 | |
| Current price drop from All-time high | -98.43% | -12.29% |
| Highest price drop | -99.39% | -56.47% |
| Date of highest drop | 21 Nov 2024 | 9 Mar 2009 |
| Avg drop from high | -56.01% | -11.07% |
| Avg time to new high | 51 days | 12 days |
| Max time to new high | 1922 days | 1805 days |
COMPANY DETAILS
Marketcap
134.79M
Marketcap category
Small-cap
Description
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.
Employees
108
Investor relations
-
SEC filings
CEO
Country
France
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
No items found